[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:malignant-ovarian-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":392},"Malignant Ovarian Neoplasm",343,300,[8,16,23,29,36,42,48,54,60,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,193,198,204,210,216,222,228,234,240,246,252,259,265,271,277,283,288,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06386146","JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.751547Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04918186","Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer",[20],"Phase 2","2026-08-26T02:17:40.683658Z","2026-05-05T02:43:29.723499Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07023627","A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[20],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:29.352359Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05225363","Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer",[33],"Phase 1","2026-08-26T02:16:45.157238Z","2026-05-05T02:43:29.337860Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06303505","FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r\u002Fr Adenocarcinoma NSCLC",[12],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:29.284291Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05998135","Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.219960Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05123807","Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)",[20],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:29.134872Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04469764","Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer",[20],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:28.703321Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT07225270","Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy",[64],"Phase 3","2026-08-26T02:15:40.343619Z","2026-05-05T02:43:28.629365Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04315233","Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics",[33],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.500775Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06083844","Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy",[20],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.496123Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07303894","A Study of Isoquercetin in People With Ovarian Cancer",[20],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:28.472398Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07030907","A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer",[33],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:28.370443Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06710288","A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer",[20],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.341434Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06964009","DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer",[33],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:28.099090Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06040970","Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer",[12],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:27.837801Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06268665","Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:27.833757Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05950464","Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer",[33],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.816353Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06646627","Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors",[33],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.747311Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05636111","Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer",[33],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:27.670737Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06815497","Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.635063Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06188520","A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:27.078571Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04585958","Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer",[33],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:27.053677Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06234423","A Study of CUSP06 in Patients With Platinum-Refractory\u002FResistant Ovarian Cancer and Other Advanced Solid Tumors",[33],"2026-08-26T02:19:07.104270Z","2026-05-05T02:35:31.903897Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT04633239","Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer",[33],"2026-08-26T02:17:33.002248Z","2026-04-29T02:57:57.068634Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT07318558","A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)",[64],"2026-08-26T02:19:14.560989Z","2026-07-24T01:27:14.897512Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer",[12],"2026-08-26T02:15:23.202838Z","2026-07-19T19:36:05.068641Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06321484","Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer",[33],"2026-08-26T02:18:08.005333Z","2026-07-05T05:32:16.754624Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)",[12],"2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.697930Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT06803680","A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",[33],"2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.694406Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":65,"content_modified":197},"NCT07059845","A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer",[20],"2026-06-04T01:30:07.896241Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07546500","A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression",[64],"2026-08-26T02:16:48.735701Z","2026-05-29T15:36:40.191734Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06639074","Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial",[20],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.723942Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT07356453","A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.",[33],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:29.669064Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer",[33],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:29.538962Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT06366490","Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer",[33],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.471463Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib",[20],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.336719Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06580314","Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer",[64],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.331227Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors",[12],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.324355Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT06617923","Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer",[20],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.295095Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":257,"content_modified":258},"NCT06161025","A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[256],"Phase 2\u002FPhase 3","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.195828Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT05610735","Combination Therapy for Recurrent Ovarian Cancer",[12],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.195795Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT06888921","A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer",[12],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:29.182828Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT07306559","A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)",[33],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.158628Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT05920798","Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[12],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.054306Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":281,"content_modified":287},"NCT05231122","Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer",[20],"2026-05-05T02:43:29.046114Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":257,"content_modified":293},"NCT05080946","Using Aspirin to Improve Immunological Features of Ovarian Tumors",[292],"Early Phase 1","2026-05-05T02:43:29.041300Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT07214779","Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression",[64],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.882083Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[33],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":83,"content_modified":310},"NCT05942300","CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer",[33],"2026-05-05T02:43:28.855543Z",[312,316,320,324,328,332,335,338,341,344,347,351,354,357,360,363,367,370,374,377,380,383,386,389],{"biomarker":313,"count":314,"slug":315},"BRCA1 Gene",15,"brca1-gene",{"biomarker":317,"count":318,"slug":319},"BRCA2 Gene",11,"brca2-gene",{"biomarker":321,"count":322,"slug":323},"MSI1 Gene",9,"msi1-gene",{"biomarker":325,"count":326,"slug":327},"G1\u002FS-Specific Cyclin-E1",7,"g1-s-specific-cyclin-e1",{"biomarker":329,"count":330,"slug":331},"BRCA Gene Family",6,"brca-gene-family",{"biomarker":333,"count":330,"slug":334},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":336,"count":330,"slug":337},"Partner and Localizer of BRCA2","partner-and-localizer-of-brca2",{"biomarker":339,"count":330,"slug":340},"RAD51C Gene","rad51c-gene",{"biomarker":342,"count":330,"slug":343},"RAD51D Gene","rad51d-gene",{"biomarker":345,"count":330,"slug":346},"TBCE wt Allele","tbce-wt-allele",{"biomarker":348,"count":349,"slug":350},"CLDN6 Gene",5,"cldn6-gene",{"biomarker":352,"count":349,"slug":353},"ERBB2 Gene","erbb2-gene",{"biomarker":355,"count":349,"slug":356},"Folate Receptor Alpha","folate-receptor-alpha",{"biomarker":358,"count":349,"slug":359},"GTPase KRas","gtpase-kras",{"biomarker":361,"count":349,"slug":362},"TP53 Gene","tp53-gene",{"biomarker":364,"count":365,"slug":366},"BRAF Gene",4,"braf-gene",{"biomarker":368,"count":365,"slug":369},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain","hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",{"biomarker":371,"count":372,"slug":373},"AHRR Gene",3,"ahrr-gene",{"biomarker":375,"count":372,"slug":376},"AT-Rich Interactive Domain-Containing Protein 1A","at-rich-interactive-domain-containing-protein-1a",{"biomarker":378,"count":372,"slug":379},"BRIP1 Gene","brip1-gene",{"biomarker":381,"count":372,"slug":382},"CD276 wt Allele","cd276-wt-allele",{"biomarker":384,"count":372,"slug":385},"FRα","fr",{"biomarker":387,"count":372,"slug":388},"MSLN Gene","msln-gene",{"biomarker":390,"count":372,"slug":391},"PIK3CA Gene","pik3ca-gene",[393,397,401,405,409,413,416,420,424,428,432,436,440,444,448,452,456,459,463,467,470,474,478,482],{"state":394,"count":395,"slug":396},"Texas",172,"texas",{"state":398,"count":399,"slug":400},"California",139,"california",{"state":402,"count":403,"slug":404},"New York",121,"new-york",{"state":406,"count":407,"slug":408},"Florida",111,"florida",{"state":410,"count":411,"slug":412},"Massachusetts",86,"massachusetts",{"state":414,"count":411,"slug":415},"Ohio","ohio",{"state":417,"count":418,"slug":419},"Pennsylvania",85,"pennsylvania",{"state":421,"count":422,"slug":423},"Virginia",79,"virginia",{"state":425,"count":426,"slug":427},"Tennessee",73,"tennessee",{"state":429,"count":430,"slug":431},"Michigan",72,"michigan",{"state":433,"count":434,"slug":435},"North Carolina",63,"north-carolina",{"state":437,"count":438,"slug":439},"Minnesota",59,"minnesota",{"state":441,"count":442,"slug":443},"Illinois",54,"illinois",{"state":445,"count":446,"slug":447},"Colorado",53,"colorado",{"state":449,"count":450,"slug":451},"Washington",49,"washington",{"state":453,"count":454,"slug":455},"Missouri",47,"missouri",{"state":457,"count":454,"slug":458},"New Jersey","new-jersey",{"state":460,"count":461,"slug":462},"Maryland",45,"maryland",{"state":464,"count":465,"slug":466},"Arizona",44,"arizona",{"state":468,"count":465,"slug":469},"Oklahoma","oklahoma",{"state":471,"count":472,"slug":473},"Georgia",39,"georgia",{"state":475,"count":476,"slug":477},"Connecticut",37,"connecticut",{"state":479,"count":480,"slug":481},"Oregon",36,"oregon",{"state":483,"count":484,"slug":485},"Kentucky",34,"kentucky"]